Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Using a new technology and computational method, researchers from Fred Hutch Cancer Center and The University of Texas MD Anderson Cancer Center have uncovered a biomarker capable of accurately ...

At least 950 voters in three cells in the Nyendo-Mukungwe division in Masaka City are in panic over the mysterious deletion of their polling stations from the Electoral Commission’s registers. The ...

JOHNSON MATTHEY is cutting its investment in green hydrogen technologies by 83% following pressure from shareholders to ...

A team from Osaka University has developed scSPOT, a new technique that reveals how immune cells called Tregs simultaneously ...

Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma ...

Doug Kellogg, professor of molecular, cell, and developmental biology at UC Santa Cruz, has been awarded $2.95 million from ...

Previous research has shown that cell division cycle associated 4 (CDCA4) is overexpressed in multiple tumors and is involved in tumor progression. Researchers from Yangtze University and affiliated ...

PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary ...

A Limestone County man faces prison time after pleading guilty to federal charges after authorities say he hacked a Twitter ...

In 2024, as part of the Army force structure (ARSTRUC) transformation, the Army Chief of Staff identified the 2nd Brigade ...

PHC has partnered with CCRM to boost cell quality with advanced T-cell expansion solutions. Takeaway Points  PHC has ...